Literature DB >> 30166014

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.

Lei Deng1, Lesli A Kiedrowski2, Elizabeth Ravera3, Haiying Cheng3, Balazs Halmos4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30166014     DOI： 10.1016/j.jtho.2018.04.007

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  17 in total

1.  Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC "capitulate"?

Authors:  Brian Ko; Balazs Halmos
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 2.  Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.

Authors:  Manan P Shah; Joel W Neal
Journal:  Drugs       Date:  2022-04-12       Impact factor: 9.546

Review 3.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

Review 4.  Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Authors:  Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Brigida Stanzione; Alberto Revelant; Kelly Fassetta; Michele Spina; Alessandra Bearz
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

5.  Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer.

Authors:  Nagio Takigawa; Nobuaki Ochi; Hiromichi Yamane
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 6.  Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy.

Authors:  Marzia Del Re; Stefania Crucitta; Giulia Gianfilippo; Antonio Passaro; Iacopo Petrini; Giuliana Restante; Angela Michelucci; Stefano Fogli; Filippo de Marinis; Camillo Porta; Antonio Chella; Romano Danesi
Journal:  Int J Mol Sci       Date:  2019-08-14       Impact factor: 5.923

7.  Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer.

Authors:  Jiangping Yang; Ping Zhou; Min Yu; Yan Zhang
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

8.  Heterogeneity response to afatinib in gastric cancer patient with uncommon epidermal growth factor receptor (EGFR) mutations: a case report.

Authors:  Qin Liu; Yang Yang; Xiangshan Fan; Xiaoyan Xin; Qiuyue Pan; Yihong Zhang; Baorui Liu; Jia Wei
Journal:  Ann Transl Med       Date:  2021-05

9.  Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.

Authors:  Rui Han; Shuai Hao; Conghua Lu; Chong Zhang; Caiyu Lin; Li Li; Yubo Wang; Chen Hu; Yong He
Journal:  Mol Oncol       Date:  2020-05-05       Impact factor: 6.603

Review 10.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Authors:  Alessandro Leonetti; Sugandhi Sharma; Roberta Minari; Paola Perego; Elisa Giovannetti; Marcello Tiseo
Journal:  Br J Cancer       Date:  2019-09-30       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.